Ultragenyx Pharmaceutical Inc. (RARE)

Ultragenyx Pharmaceutical Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Year Ending	Current	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	3,854	3,927	3,248	5,732	8,450	2,467
Market Cap Growth	36.53%	20.90%	-43.33%	-32.17%	242.48%	12.20%
Enterprise Value	3,482	3,393	2,532	5,034	7,297	1,749
PE Ratio	-	-6.47	-4.59	-12.62	-45.29	-6.13
PS Ratio	8.71	9.04	8.94	16.31	31.18	23.79
PB Ratio	27.47	14.26	9.21	6.21	7.32	3.77
P/FCF Ratio	-7.24	-7.56	-6.54	-13.92	-47.98	-6.66
P/OCF Ratio	-7.56	-8.27	-8.54	-16.92	-63.91	-7.14
EV/Sales Ratio	7.87	7.81	6.97	14.32	26.92	16.87
EV/EBITDA Ratio	-5.93	-5.82	-3.70	-11.45	-42.16	-4.47
EV/EBIT Ratio	-5.65	-5.58	-3.61	-11.11	-39.37	-4.38
EV/FCF Ratio	-6.54	-6.54	-5.10	-12.22	-41.43	-4.72
Debt / Equity Ratio	0.29	0.16	0.09	0.05	0.04	0.06
Debt / EBITDA Ratio	-0.07	-0.07	-0.05	-0.10	-0.28	-0.09
Debt / FCF Ratio	-0.08	-0.08	-0.06	-0.10	-0.27	-0.10
Quick Ratio	2.09	2.32	3.02	4.24	6.46	7.63
Current Ratio	2.43	2.61	3.38	4.72	6.83	8.24
Asset Turnover	0.33	0.32	0.25	0.23	0.19	0.10
Return on Equity (ROE)	-425.60%	-369.50%	-123.30%	-46.80%	-23.90%	-52.20%
Return on Assets (ROA)	-45.90%	-44.70%	-48.20%	-29.70%	-13.40%	-40.50%
Return on Capital (ROIC)	-321.00%	-178.77%	-169.36%	-39.75%	-27.45%	-61.41%
Earnings Yield	-15.92%	-15.45%	-21.78%	-7.92%	-2.21%	-16.32%
FCF Yield	-13.78%	-13.22%	-15.29%	-7.18%	-2.08%	-15.00%
Buyback Yield / Dilution	-19.78%	-5.19%	-3.13%	-11.42%	-7.54%	-13.66%
Total Shareholder Return	-19.78%	-5.19%	-3.13%	-11.42%	-7.54%	-13.66%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).